Samiksha Jaiswal (Editor)

Rabeprazole

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
AHFS/Drugs.com
  
Monograph

Routes of administration
  
Oral

Molar mass
  
359.444 g/mol

Bioavailability
  
52%

MedlinePlus
  
a699060

ATC code
  
A02BC04 (WHO)

CAS ID
  
117976-89-3

Rabeprazole

License data
  
US FDA: Finix&SearchType=BasicSearch AcipHex Finix

Pregnancy category
  
US: B (No risk in non-human studies)

Rabeprazole with antiplatelet drugs dr naresh sen


Rabeprazole /ˌræ.ˈbɛp.ræ.zɔːl/ is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is available worldwide under many brand names.

Contents

Indications and usage

Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.

  • Gastric ulcer (GU)
  • Peptic ulcer disease (PUD)
  • Maintenance of healing of erosive or ulcerative GERD
  • Healing of erosive and ulcerative GERD
  • Healing of duodenal ulcers.
  • Treatment of symptomatic GERD
  • Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
  • Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence

    • Contraindications

  • hypersensitivity to rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
  • lactation: Thomson Lactation Ratings: Infant risk cannot be ruled out.

    • Restriction of usage

  • acute liver failure
  • pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of rabeprazole in this group of patients)

    • Side effects

    Rabeprazole adverse reactions/side effects include:

  • In clinical trials the most common side effect assessed as possibly or probably related to AcipHex was headache in 2.4% of patients vs 1.6% taking placebo.
  • abdominal pains
  • anxiety
  • arthralgia
  • asthenia
  • constipation
  • diarrhea
  • dry mouth
  • erythema
  • granulocytopenia
  • headache
  • increased or decreased appetite
  • insomnia
  • leukocytopenia
  • meteorism
  • muscle or bone pain
  • myalgia
  • nausea
  • skin eruption
  • thrombocytopenia
  • vertigo
  • vomiting

    • Drug interactions

    Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).

    Overdosage

    Studies in mice and rats indicated the symptoms of acute toxicity due to overdose included: hypoactivity, labored respiration, convulsion, diarrhea, tremor, and coma. A study in dogs indicated that a dose of 2000 mg/kg was not lethal.

    Synthesis

    Nitration of 2,3-dimethylpyridine N-oxide affords the nitro derivative. The newly introduced nitro group is then displaced by the alkoxide from 3-methoxypropanol to affords the corresponding ether (3). Treatment with acetic anhydride results in the Polonovski reaction. Saponification followed by treatment with thionyl chloride then chlorinates the primary alcohol (5). Reaction with benzimidazole-2-thiol (6) followed by oxidation of the resulting thioether to the sulfoxide then affords rabeprazole (8).

    References

    Rabeprazole Wikipedia
    (Text) CC BY-SA